A DIVISION OF THE

Pharmaceutical Care Management Association

PCMA Applauds the Administration’s Effort to Combat the Opioid Crisis

(Washington, D.C.) — As the Administration puts forward new steps to curb the rising opioid epidemic, the Pharmaceutical Care Management Association (PCMA) is offering policy solutions to leverage the ability of pharmacy benefit managers (PBMs), providers, and others to address this crisis. “PBMs have offered concrete solutions...

Read More

PCMA Response to Wall Street Journal PBM Article

In its attempt to find the reason for the high cost of Epipens, “Behind the Push to Keep Higher Priced Epipen in Consumer’s Hands” ignores the most obvious fact: Mylan raised prices 600%. Instead it implies the problem is Pharmacy Benefit Managers (PBMs) encouraging plan...

Read More

PCMA Offers to Work with FDA chief Scott Gottlieb to Address the Opioid Crisis

The Pharmaceutical Care Management Association (PCMA) has outlined solutions that would help assure people receive opioid prescriptions only when medically appropriate. Click here for the letter. These common-sense measures include: Endorse the Centers for Disease Control and Prevention’s (CDC’s) Guideline for Opioid Prescribing Require E-prescribing (e-Rx) for...

Read More

PCMA Report: Drugmakers Raise Prices Regardless of Rebates

Prices Rise Even When Rebates Are Low Rebates Also Unrelated to the Launch Prices of New Drugs (Washington, D.C.) — As the Senate Committee on Health, Education, Labor and Pensions examines the drug delivery system during a hearing tomorrow, the Pharmaceutical Care Management Association (PCMA)...

Read More

PBMs Provide Clinical Value to Patients, Doctors, and Other Healthcare Providers

Pharmacy Benefit Managers (PBMs) are critical to the delivery of high-quality, cost-effective healthcare. PBMs have long been recognized for their ability to create savings through providing clinical utilization management programs, offering more affordable pharmacy channels, negotiating discounts with drug manufacturers and retail drugstores, and encouraging...

Read More

PCMA: New Market Analysis Shows No Connection Between Drugmaker Pricing and Rebates

(Washington, D.C.) — A new market analysis contradicts claims that drug pricing is contingent on the level of rebates and discounts manufacturers negotiate with the pharmacy benefit managers (PBMs) that represent employer, union, and government plans offering prescription drug coverage. Visante analyzed data on gross and net sales for the top 200 self-administered, patent-protected, brand-name drugs and found no correlation between the price drugmakers set...

Read More

PCMA: Drugmaker Lobby Campaign Deflects Blame for High Drug Prices

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement regarding the drugmaker lobby’s campaign to deflect blame for high drug prices: “This latest campaign is an attempt to deflect blame for high drug prices onto the employers, unions, and insurers that...

Read More

PCMA: PhRMA Report on Cost-Sharing Misses the Mark

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following points regarding a new PhRMA report on patient out-of-pocket spending: According to the Centers for Medicare and Medicaid Services (CMS), the average amount spent out-of-pocket for drugs continues to decline, projected to...

Read More

PCMA: C-THRU Act Will Increase Costs, Undermine Competition

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on legislation introduced by Senator Ron Wyden (D-OR), “The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act”: “America’s most sophisticated purchasers—employers, unions, government health programs—choose to hire pharmacy benefit managers (PBMs)...

Read More

PCMA: New Drugstore Lobby Bill Would Increase Prescription Drug Costs

(Washington, D.C.) —Legislation championed by the various special interest drugstore lobbies (H.R. 1316, The Prescription Drug Price Transparency Act) and introduced by Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa), would increase the cost of prescription drugs in federal health programs, including TRICARE and the Federal...

Read More

PCMA: DIR Legislation Would Increase Premiums, Medicare Part D Costs

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on H.R. 1038, legislation introduced by Reps. Morgan Griffith (R-VA) and Peter Welch (D-VT), that would prohibit Medicare Part D plans from using direct and indirect remuneration (DIR) for pharmacies in Part...

Read More

PCMA Releases New Video: “What is Drug Price Transparency?”

(Washington, D.C.) — As part of its DrugBenefitSolutions.com campaign, the Pharmaceutical Care Management Association (PCMA) today released a new video, “What is drug price transparency?” explaining how transparency is widely used in the prescription drug marketplace for patients and employers, and highlighting that “the wrong...

Read More

PCMA Statement on New Class-Action Lawsuit Against Drug Companies

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s new class-action lawsuit against three makers of insulin drug products: “While we’re still reviewing the details of the lawsuit – in which pharmacy benefit managers (PBMs) are not named as...

Read More

PCMA Statement on Gov. Cuomo’s NY Prescription Drug Price Proposal

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new proposal by Governor Andrew Cuomo (D-NY) that includes regulations on pharmacy benefit managers (PBMs): “This mandate would increase costs by tying the hands of employers, unions, and public programs...

Read More

New Research: PBMs Save $941 Per Person Annually

(Washington, D.C.) — Pharmacy benefit managers (PBMs) are saving consumers and payers an average of $941 per person per year, according to a new analysis by Visante. The new research also highlights PBMs’ role in reducing medication errors and improving the lives of patients through...

Read More

PCMA Offers Policy Recommendations to Stem Rx Abuse, Reduce Costs

(Washington, D.C.) —Testifying before the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law, Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt offered policy recommendations to help stem the rising tide of drug abuse and reduce costs at the hearing, Treating the...

Read More

PCMA Statement on Oversight Committee Hearing on EpiPen Price Hikes

(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on today’s House Committee on Oversight and Government Reform hearing, “Reviewing the Rising Price of EpiPens:” “For EpiPens, price concessions negotiated by pharmacy benefit managers (PBMs) have significantly reduced...

Read More

Survey on Drug Costs: Employers Prefer Private Sector Solutions

(Washington, D.C.) — America’s employers are concerned about high drug prices and think private sector solutions would address the issue more effectively than government intervention, according to a national survey from North Star Opinion Research released by the Pharmaceutical Care Management Association (PCMA). By a...

Read More

PCMA on New PwC Report: PBMs Driving Competition to Reduce Drug Costs

June 21, 2016 (Washington, D.C.) — The new PwC Health Research Institute (HRI) annual report (“Medical Cost Trend: Behind the Numbers 2017”) highlights how pharmacy benefit managers (PBMs) help reduce drug cost trend, specifically noting that: “With increased appetite from employers to narrow their formularies...

Read More

PCMA Launches Second Phase of “That’s What PBMs Do” Campaign

June 13, 2016 Campaign Highlights How Specialty and Preferred Pharmacy Networks Help Patients, Reduce Costs (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today launched the second phase of its That’s What PBMs Do campaign with two new videos explaining how specialty pharmacies and...

Read More

PBM Policy Forum 2016

The PCMA PBM Policy Forum was hosted April 11, 2016 in Washington, DC. The forum, focused on the cost of prescription drugs and the latest efforts to bring those costs down, brought together healthcare and drug industry advocates from think tanks, patient advocacy groups, and...

Read More

PCMA Statement on the FDA’s Decision to Approve the Second U.S. Biosimilar

April 6, 2016 Increased Competition Lowers Drug Costs (Washington, D.C.)—Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on yesterday’s decision by the Food and Drug Administration (FDA) to approve Inflectra, the second biosimilar approved in the United States. Inflectra...

Read More

PCMA Launches New Campaign: ‘That’s What PBMs Do’

March 17, 2016 Campaign shows how PBMs reduce costs, improve pharmacy benefits, and features new national and state-specific savings data, video, and ads (Washington D.C.)— As policymakers seek solutions to combat high drug prices, the Pharmaceutical Care Management Association (PCMA) is launching a new national...

Read More

PBMs Provide Policy Solutions to Increase Competition, Reduce Rx Costs

February 4, 2016 (Washington, D.C.)— Testifying before the House Committee on Oversight and Government Reform, Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt outlined market-based policy solutions to help increase competition and lower prescription drug costs. The Committee is examining “methods and reasoning...

Read More

PCMA: Increase Competition to Reduce Prescription Drug Costs

November 20, 2015 (Washington D.C.)— Stakeholders at today’s Health and Human Services (HHS) Pharmaceutical Forum should examine ways to increase competition and eliminate delays in drug approvals that would in turn lower costs and improve patient access, the Pharmaceutical Care Management Association (PCMA) said. “The...

Read More

New Pharmacy Mandates Would Increase Rx Costs, Undermine Competition

November 17, 2015 (Washington D.C.)—As the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law examines competition “in the pharmacy benefit managers and pharmacy marketplaces,” policymakers should examine how greater use of pharmacy benefit management tools lower prescription drug costs, enhances access and improves...

Read More

PCMA Outlines 2015 Policy Agenda

January 21, 2015 Promote Lower Cost Pharmacy Options, Increase Competition, Reduce Health Care Fraud, Waste, and Abuse (Washington D.C.)—The Pharmaceutical Care Management Association (PCMA) today released its 2015 policy agenda, which includes reducing prescription drug costs for consumers, employers, unions, Medicare Part D, and other government...

Read More

PCMA Statement on 21st Century Cures

May 21, 2015 (Washington, D.C.)—The Pharmaceutical Care Management Association (PCMA) issued the following statement regarding the Medicare Part D offsets included in the Energy & Commerce Committee’s 21st Century Cures initiative: “If the 21st Century Cures initiative can only be advanced by cutting billions from...

Read More

325 7th Street, NW, 9th Floor, Washington, DC 20004
(202) 756-5700    Privacy Policy & Terms of Use